Skip to main content
ELV logo

Elevance Health Inc. (ELV) Stock: Price, Forecast & Analyst Target

Elevance Health Inc. (ELV) — MoonshotScore 88/100 (Exceptional band), calculated Nov 18, 2026. Price $390.16 (-2.66%), as of the Nov 19, 2026 trading session; market cap $84.3B. Expected results Jan 27, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$390.16 −$10.68 (-2.66%) Market Cap $84.3B

Elevance Health Inc. · ELV · NYSE · Healthcare · Medical - Healthcare Plans

Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path.

Price as of Nov 19, 2026

Key Statistics

88 of 100

MoonshotScore v2 · Elevance Health (ELV)

Exceptional
Business Quality Elite (84)
Financial Safety Okay (45)
Valuation Cheap (84)
Growth Durability Compounding (88)
Momentum Surging (87)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and elite growth, at a cheap price, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • expected results Jan 27, 2027
  • Altman Z 3.07 · Piotroski F 7

Helping: business quality, an attractive price, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ELV (57 recorded, newest six shown)
RecordedScoreBand
87Exceptional
87Exceptional
87Exceptional
87Exceptional
88Exceptional
88Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$390.16
Change on the day-2.66%
52-week range$274.84–$450.69
Market capitalisation$84.3B—
Price / earnings (trailing)18.48
Shares traded on the day2.73M
Beta (volatility vs the S&P 500)0.71

Why Elevance Health scores 88

Dr. Mira Sol, the Stock Expert AI TV data character
Growth Durability carries the score; Financial Safety is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
88Exceptional
  • Business Quality84
  • Financial Safety45
  • Valuation84
  • Growth Durability88
  • Momentum87

Share price, last 12 months +41.4%

$303.78 $429.65

What the price assumes

2.6% a year of free-cash-flow growth for ten years is what a $92.83B market value ( snapshot) asks for.

  • Price implies, next ten years2.6%
  • Free cash flow, last 5 years-20.0%
  • Revenue, last 5 years10.3%
  • Analysts' revenue path, 2026–20304.4%

The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $6.51B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 10 of the last 12 reports (2024–2026); the stock still fell the next session after 3 of those beats. Average first-session move: 7.1% either way.

  1. +1.7%Jan ’24
  2. +4.4%Apr ’24
  3. -8.8%Jul ’24
  4. -13.3%Oct ’24
  5. +2.6%Jan ’25
  6. +5.0%Apr ’25
  7. -19.6%Jul ’25
  8. -2.5%Oct ’25
  9. +7.5%Jan ’26
  10. +5.5%Apr ’26
  11. -12.6%Jul ’26
  12. +1.2%Oct ’26
Next-session move EPS beat (10) EPS in line (1) EPS miss (1)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
BeatBeat+1.2%-5.9%
BeatBeat-12.6%-8.8%
BeatBeat+5.5%+14.8%
BeatMiss+7.5%+5.5%
BeatBeat-2.5%-4.1%
In lineBeat-19.6%-18.6%
BeatBeat+5.0%+1.7%
BeatBeat+2.6%+2.2%
MissBeat-13.3%-15.7%
BeatBeat-8.8%-7.4%
BeatIn line+4.4%+6.0%
BeatBeat+1.7%+4.5%

Beats have usually been rewarded — 7 of 10 drew a higher close the next session.

What management is saying differently

Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.

  • New this call: “rate actions”, “greater operating”, “recent rate”, “share growth” — none of them came up in Q2 FY2026.
  • Getting louder: “margin improvement” (2 → 7 mentions), “selling season” (2 → 7 mentions), “health benefits” (2 → 5 mentions).
  • Gone quiet: “broadly aligned”, “provider connectivity”, “outpatient surgery”, “sustainable performance” — regular themes last call, absent this time.

The tone held steady from one call to the next; what changed is the subject matter, not the confidence.

Our track record on this stock

Since the score went from 86 to 88 while the share price moved -3.1% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range

The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 71% of 38 rate it a buy; the average target sits +19.6% from the price of $390.16.
  • Last 90 days: 10 rating actions, every one a reaffirmation.
  • Our signals: Exceptional band; strongest pillar Growth Durability (88), weakest Financial Safety (45).

Here we and the crowd agree.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $286, high $440, latest $390. 4 reported quarters marked, 4 above and 0 below the recorded estimate. $440 $286 high $440 Jan 28, 2026 · Earnings results · reported above the recorded estimate · close $3461Apr 22, 2026 · Earnings results · reported above the recorded estimate · close $3452Jul 15, 2026 · Earnings results · reported above the recorded estimate · close $3733Oct 21, 2026 · Earnings results · reported above the recorded estimate · close $4404 Oct 17, 2025 Nov 19, 2026 · $390 $349Oct 17, 2025$317Oct 31, 2025$326Nov 14, 2025$338Nov 28, 2025$359Dec 12, 2025$350Dec 26, 2025$373Jan 9, 2026$371Jan 23, 2026$339Feb 6, 2026$343Feb 20, 2026$290Mar 6, 2026$291Mar 20, 2026$301Apr 2, 2026$323Apr 17, 2026$373May 1, 2026$393May 15, 2026$393May 29, 2026$404Jun 12, 2026$395Jun 26, 2026$416Jul 10, 2026$378Jul 24, 2026$394Aug 7, 2026$401Aug 21, 2026$408Sep 4, 2026$411Sep 18, 2026$386Oct 2, 2026$428Oct 16, 2026$420Oct 30, 2026$430Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Elevance Health (ELV): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Strong
Growth Durability Strong
Momentum Strong

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Weak
ROE Neutral
Gross Margin Neutral

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Elevance Health (ELV), and what does it report?

Short answer

Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. Elevance Health Inc. (ELV) is listed on NYSE. Healthcare / Medical Healthcare Plans SEC filing business address: Indianapolis, IN. It employs 96,615 people and is led by Gail Koziara Boudreaux. The market values it at $84.3B.

2 · Latest results

What do the latest results show for Elevance Health (ELV)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$50.44B Oct 21, 2026
Latest report · revenue estimate
$49.28B Oct 21, 2026
Latest report · revenue vs estimate
Above estimate Oct 21, 2026
Latest report · EPS vs estimate
Above estimate Oct 21, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 21, 2026$50.44B$49.28B$6.9900$4.7100
Jul 15, 2026$49.83B$48.88B$7.4500$6.2100
Apr 22, 2026$49.49B$48.20B$12.5800$10.8200
Jan 28, 2026$49.31B$49.84B$3.3300$3.1000
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$50.71B$1.19B$5.32 (diluted)
Q4 FY2025$49.75B$547M$2.47 (diluted)
Q1 FY2026$50.18B$1.76B$8.00 (diluted)
Q2 FY2026$50.47B$1.46B$6.71 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Elevance Health (ELV)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway. The MoonshotScore pillars rate business quality, an attractive price, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 3.07 · Piotroski F 7. Trailing ratios: ROE 11.5% · ROA 4.0% · current ratio 1.47.

4 · What to check next?

What should you watch next at Elevance Health (ELV)?

Short answer · as of

The next earnings report is expected on Jan 27, 2027. Current published price targets run low $395.00 · high $523.00 · consensus $470.11 · median $478.50 against a quoted price of $390.16 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Elevance Health compare with its peers?

Short answer

Elevance Health's score ranks 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Oscar Health, Inc. (OSCR) Same industry, near in market value$26.17 Nov 19, 2026$8.13B97 5-pillar Nov 18, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Named competitor$945.53 Nov 18, 2026$97.8B95 5-pillar Nov 18, 2026
Clover Health Investments, Corp. (CLOV) Same industry, near in market value$3.77 Nov 19, 2026$2.02B94 5-pillar Nov 18, 2026
Centene Corporation (CNC) Same industry, near in market value$65.62 Nov 19, 2026$32.5B91 5-pillar Nov 18, 2026
Elevance Health (ELV) — this page$390.16$84.3B88
Cencora, Inc. (COR) Named competitor$341.25 Nov 19, 2026$65.1B86 5-pillar Nov 18, 2026
CVS Health Corporation (CVS) Named competitor$80.06 Nov 19, 2026$102B81 5-pillar Nov 18, 2026
Humana Inc. (HUM) Same industry, near in market value$380.00 Nov 19, 2026$45.6B79 5-pillar Nov 18, 2026
Cigna Corporation (CI) Named competitor$273.09 Nov 19, 2026$72.0B78 5-pillar Nov 18, 2026
GSK plc (GSK) Named competitor$48.58 Nov 18, 2026$97.4B77 5-pillar Nov 18, 2026
UnitedHealth Group Incorporated (UNH) Same industry, near in market value$349.91 Nov 18, 2026$314B76 5-pillar Nov 18, 2026
Alignment Healthcare, Inc. (ALHC) Same industry, near in market value$6.72 Nov 18, 2026$1.41B73 5-pillar Nov 18, 2026
Molina Healthcare, Inc. (MOH) Same industry, near in market value$203.34 Nov 19, 2026$10.6B68 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$395.00 – $523.00
Consensus target
$470.11
Median target
$478.50

Consensus record · Captured .

Measured against a quoted price of $390.16 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026

Transactions
24
Identified insiders
8
Purchases
3
Sales
16
Other transactions
5

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ELV in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Baupost GroupSeth KlarmanQ3 20269.83%$495.81MHeld, unchanged

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Elevance Health (ELV)?

Read these with our analysis →

What Investors Ask About Elevance Health (ELV) — Healthcare

These answers are editorial: 1 of these 8 answers is drawn from the ELV research dossier (written May 10, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ELV?

ELV carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is ELV a good stock to buy?

Stock Expert AI does not rate ELV buy, sell or hold. Elevance Health Inc. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ELV stock price today?

The last price recorded for Elevance Health Inc. (ELV), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ELV price target?

The analyst consensus price target for Elevance Health Inc. (ELV), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about ELV stock?

Analysts generally view Elevance Health favorably, citing its strong market position, diversified service offerings, and growth potential. Key valuation metrics such as P/E ratio and dividend yield suggest a reasonable valuation relative to earnings and a steady income stream for investors. Analysts also highlight the company's focus on digital health and value-based care as positive drivers for future growth.

What are the key factors to evaluate for ELV?

Elevance Health Inc. (ELV) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.

How frequently does ELV data refresh on this page?

ELV's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ELV's recent stock price performance?

Elevance Health Inc. (ELV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 46 figures on this page — 1 from SEC filings and earnings calls, 38 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold ELV

Funds in our ETF coverage that list ELV among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
IHF ETF9.29%